Erosive vulvo–vaginal lichen planus treated with rituximab: A case report

Lagerstedt, Maria; Kotaniemi-Talonen, Laura; Antonen, Jaakko; Vaalasti, Annikki

doi:10.1002/ijgo.13814

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas the pathogenic role of IgG anti-BP180 has been validated in BP ( 50 ), their pathogenicity is less demonstrated in MMP, but rituximab efficacy was reported in a large series ( 51 ). On the other hand, rituximab efficacy has been uncertain in small series of erosive lichen planus without AIBD, whose immunopathology is more T cell driven ( 52 , 53 ). This may explain why the two patients who received rituximab still had active disease.…”

Section: Discussionmentioning

confidence: 99%

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Combemale,

Bohelay,

Sitbon

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundLichen planus pemphigoides (LPP), an association between lichen planus and bullous pemphigoid lesions, is a rare subepithelial autoimmune bullous disease. Mucous membrane involvement has been reported previously; however, it has never been specifically studied.MethodsWe report on 12 cases of LPP with predominant or exclusive mucous membrane involvement. The diagnosis of LPP was based on the presence of lichenoid infiltrates in histology and immune deposits in the basement membrane zone in direct immunofluorescence and/or immunoelectron microscopy. Our systematic review of the literature, performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, highlights the clinical and immunological characteristics of LPP, with or without mucous membrane involvement.ResultsCorticosteroids are the most frequently used treatment, with better outcomes in LPP with skin involvement alone than in that with mucous membrane involvement. Our results suggest that immunomodulators represent an alternative first-line treatment for patients with predominant mucous membrane involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Combemale,

Bohelay,

Sitbon

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Endoscopy also demonstrated complete remission of esophageal involvement at month 3 [ 158 ]. Three additional case reports of four patients with refractory oral and vulvovaginal erosive LP reported successful treatment with rituximab [ 159 – 161 ]. One case report of lichen planopilaris in a patient with juvenile chronic arthritis described rapid and complete resolution with rituximab treatment [ 162 ]; however, a retrospective study of five patients with refractory erosive LP reported failure or transient minimal improvement with rituximab.…”

Section: Autoimmune Diseases Of the Skinmentioning

confidence: 99%

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin

Nedosekin

Wong

2023

Am J Clin Dermatol

View full text Add to dashboard Cite

Biologic therapies targeting B-cells are emerging as an effective strategy to treat a variety of immune-mediated diseases. One of the most studied B-cell-targeted therapies is rituximab, an anti-CD20 monoclonal antibody that exemplifies B-cell depletion therapy and has served as the prototype for other anti-CD20 monoclonal antibodies and the development of biosimilars. While there are multiple studies on the use of rituximab in dermatology, a comprehensive review of rituximab therapy in autoimmune skin conditions is lacking. In this literature review, we summarize indications, treatment efficacy, and safety of rituximab among common autoimmune diseases of the skin: pemphigus vulgaris, cutaneous lupus erythematous, dermatomyositis, systemic sclerosis, thyroid dermopathy, autoimmune pemphigoid diseases, and cutaneous vasculitis diseases. Existing data on rituximab support the approach of rituximab, biosimilars, and newer B-cell-targeting therapies in immune-mediated cutaneous diseases. Overall, rituximab, which targets CD20, provides an effective alternative or concomitant option to traditional immunosuppressants in the management of various autoimmune diseases of the skin. Further studies are necessary to expand the understanding and possible utility of B-cell-targeted therapies among autoimmune skin diseases.

show abstract

Lichen Planus: What is New in Diagnosis and Treatment?

Tekin,

Xie,

Lehman

2024

Am J Clin Dermatol

View full text Add to dashboard Cite

Erosive vulvo–vaginal lichen planus treated with rituximab: A case report

Abstract: SynopsisRituximab is an effective treatment for erosive vulvo–vaginal and oral lichen planus.

Cited by 4 publications

References 4 publications

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin

Lichen Planus: What is New in Diagnosis and Treatment?

Contact Info

Product

Resources

About